A PARP1-related prognostic signature constructing and PARP-1 inhibitors screening for glioma

A PARP1-related prognostic signature constructing and PARP-1 inhibitors screening for glioma

The current standard treatments of glioma include surgical resection, supplemented with radiotherapy and chemotherapy, but the prognosis is poor. PARP-1 (Poly ADP-ribose polymerase 1) is a hot spot for cancer-targeted therapy and was reported to be significantly elevated in glioma. In this study, we...

Full description

Bibliographic Details
Main Authors:	Hui Li, Zhenhua Wang, Yuanyuan Hou, Jianxin Xi, Zhenqiang He, Han Lu, Zhishan Du, Sheng Zhong, Qunying Yang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-08-01
Series:	Frontiers in Cell and Developmental Biology
Subjects:	Glioma PARP-1 (Poly ADP-ribose polymerase 1) DNA damage repair Inhibitors drug screening
Online Access:	https://www.frontiersin.org/articles/10.3389/fcell.2022.916415/full

Similar Items

Interactions of PARP1 Inhibitors with PARP1-Nucleosome Complexes
by: Natalya Maluchenko, et al.
Published: (2022-10-01)

Editorial: Inhibiting PARP as a Strategic Target in Cancer
by: Kristin eZorn, et al.
Published: (2016-04-01)

A Review on DNA Repair Inhibition by PARP Inhibitors in Cancer Therapy
by: Shah Ashish P., et al.
Published: (2018-03-01)

DNA damage repair protein PARP1 poly (ADP-ribosyl) ates mitotic protein BUB3 regulates mitosis in HeLa cells
by: YANG Xue, et al.
Published: (2023-08-01)

The Role of PARP1 in Monocyte and Macrophage Commitment and Specification: Future Perspectives and Limitations for the Treatment of Monocyte and Macrophage Relevant Diseases with PARP Inhibitors
by: Maciej Sobczak, et al.
Published: (2020-09-01)

Structurally unique PARP‐1 inhibitors for the treatment of prostate cancer
by: Ali Divan, et al.
Published: (2020-04-01)

Human PARP1 Facilitates Transcription through a Nucleosome and Histone Displacement by Pol II In Vitro
by: Elena Y. Kotova, et al.
Published: (2022-06-01)

Mechanism of PARP inhibitor resistance and potential overcoming strategies
by: Xiaoyu Fu, et al.
Published: (2024-01-01)

PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting
by: Karolina N. Dziadkowiec, et al.
Published: (2017-02-01)

PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling
by: Lotte van Beek, et al.
Published: (2021-05-01)

Resistance to PARP-inhibitors in Cancer Therapy
by: Alicia eMontoni, et al.
Published: (2013-02-01)

Structural implications for selective targeting of PARPs
by: Jamin D. Steffen, et al.
Published: (2013-12-01)

PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities
by: Hao-Wen Sim, et al.
Published: (2022-02-01)

A Novel PARP Inhibitor YHP-836 For the Treatment of BRCA-Deficiency Cancers
by: Tingting Du, et al.
Published: (2022-07-01)

A New Opportunity for “Old” Molecules: Targeting PARP1 Activity through a Non-Enzymatic Mechanism
by: Pablo Iglesias, et al.
Published: (2023-05-01)

PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?
by: Amelia Barcellini, et al.
Published: (2021-10-01)

Correlation between serum level of PARP1 and vascular calcification in hemodialysis patients
by: Hui Zhang, et al.
Published: (2023-10-01)

PARP Traps Rescue the Pro-Inflammatory Response of Human Macrophages in the In Vitro Model of LPS-Induced Tolerance
by: Julita Pietrzak, et al.
Published: (2021-02-01)

PARP Inhibitors Resistance: Mechanisms and Perspectives
by: Elena Giudice, et al.
Published: (2022-03-01)

Active Targeted Nanoparticles for Delivery of Poly(ADP-ribose) Polymerase (PARP) Inhibitors: A Preliminary Review
by: Saman Sargazi, et al.
Published: (2021-09-01)

Targeting PARP1 to Enhance Anticancer Checkpoint Immunotherapy Response: Rationale and Clinical Implications
by: Carlos Wagner S. Wanderley, et al.
Published: (2022-04-01)

Poly(ADP-Ribose) Glycohydrolase (PARG) vs. Poly(ADP-Ribose) Polymerase (PARP) – Function in Genome Maintenance and Relevance of Inhibitors for Anti-cancer Therapy
by: Daniel Harrision, et al.
Published: (2020-08-01)

Hematological Toxicities with PARP Inhibitors in Prostate Cancer: A Systematic Review and Meta-Analysis of Phase II/III Randomized Controlled Trials
by: Gartrell C. Bowling, et al.
Published: (2023-10-01)

Mechanisms of Nucleosome Reorganization by PARP1
by: Natalya V. Maluchenko, et al.
Published: (2021-11-01)

Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report
by: Andrew D. Simmons, et al.
Published: (2020-03-01)

PARP Inhibitors: An Innovative Approach to the Treatment of Inflammation and Metabolic Disorders in Sepsis
by: Wasyluk W, et al.
Published: (2021-05-01)

Discovery of 2-(1-(3-(4-Chloroxyphenyl)-3-oxo- propyl)pyrrolidine-3-yl)-1<i>H</i>-benzo[d]imidazole-4-carboxamide: A Potent Poly(ADP-ribose) Polymerase (PARP) Inhibitor for Treatment of Cancer
by: Rui Min, et al.
Published: (2019-05-01)

PARP12 is required for mitochondrial function maintenance in thermogenic adipocytes
by: Fan Hu, et al.
Published: (2022-12-01)

Kynurenine–PARP-1 Link Mediated by MicroRNA 210 May Be Dysregulated in Pulmonary Hypertension
by: Alperen Emre Akgun, et al.
Published: (2022-05-01)

Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and Resistance
by: Desh Deepak Singh, et al.
Published: (2021-10-01)

Strategies for the Use of Poly(adenosine diphosphate ribose) Polymerase (PARP) Inhibitors in Cancer Therapy
by: Thomas Helleday, et al.
Published: (2012-12-01)

PARP14 is increased in the hippocampus of three mouse depression models and its relationship with neuroinflammation
by: LI Chen, XIU Jian-bo, XU Qi
Published: (2021-05-01)

PARG suppresses tumorigenesis and downregulates genes controlling angiogenesis, inflammatory response, and immune cell recruitment
by: Sarah Johnson, et al.
Published: (2022-05-01)

NAD+, Sirtuins and PARPs: enhancing oocyte developmental competence
by: Charley-Lea POLLARD, et al.
Published: (2022-09-01)

Corrigendum: The critical role of PARPs in regulating innate immune responses
by: Huifang Zhu, et al.
Published: (2023-07-01)

Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy
by: Stephen A. Jannetti, et al.
Published: (2020-03-01)

New perspectives on the plant PARP family: Arabidopsis PARP3 is inactive, and PARP1 exhibits predominant poly (ADP-ribose) polymerase activity in response to DNA damage
by: Zongying Gu, et al.
Published: (2019-08-01)

PARP inhibitors in small cell lung cancer: The underlying mechanisms and clinical implications
by: Xueting Wang, et al.
Published: (2022-09-01)

Case Report: BAP1 Mutation and RAD21 Amplification as Predictive Biomarkers to PARP Inhibitor in Metastatic Intrahepatic Cholangiocarcinoma
by: Francesco Sabbatino, et al.
Published: (2020-11-01)

Transcriptomic Analysis of CRISPR/Cas9-Mediated PARP1-Knockout Cells under the Influence of Topotecan and TDP1 Inhibitor
by: Nadezhda S. Dyrkheeva, et al.
Published: (2023-03-01)